Parathyroid hormone (1-34) (human): Benchmarks for Bone and Kidney Models

Executive Summary: Parathyroid hormone (1-34) (human) is a bioactive peptide fragment that acts as an agonist for parathyroid hormone receptors, supporting both bone metabolism and kidney disease research (APExBIO product page). It has a validated IC50 of 2 nM for receptor binding and 0.22 nM for cAMP induction in kidney cells. Its solubility profile (≥399.3 mg/mL in DMSO) and storage stability at -20°C enable flexible experimental use. In vivo, it increases trabecular and cortical bone mass in rat models, facilitating osteoporosis and calcium regulation studies. Integration with spatially patterned kidney assembloids offers new paths for functional disease modeling (Huang et al., 2025).

Biological Rationale

Parathyroid hormone (1-34) (human) is a synthetic peptide corresponding to the N-terminal 34 amino acids of endogenous human parathyroid hormone. This region contains all residues required for full biological activity in calcium homeostasis (APExBIO). The hormone is secreted by chief cells of the parathyroid glands and acts as a principal regulator of serum calcium and phosphate balance. The fragment is highly conserved and functions as a parathyroid hormone 1 receptor agonist, reproducing the physiological effects of the native hormone in target tissues, notably bone and kidney. Its significance in experimental systems is amplified by the need for precise, reproducible modulation of PTH/PTHrP receptor signaling in studies of bone metabolism, osteoporosis, and renal pathophysiology.

Mechanism of Action of Parathyroid hormone (1-34) (human)

PTH (1-34) peptide fragment binds with high affinity to PTH1R and PTH2R, both class B G-protein coupled receptors expressed in bone, kidney, and other tissues. Ligand binding initiates conformational changes that activate adenylate cyclase via G_s-protein signaling, resulting in increased intracellular cAMP. This triggers downstream phosphorylation events and gene regulation, promoting osteoblastic bone formation, stimulating renal calcium reabsorption, and upregulating renal 1-α-hydroxylase to enhance intestinal calcium uptake through increased calcitriol production (Related article). At concentrations ≥24 nM, PTH (1-34) also stimulates inositol phosphate synthesis, engaging phospholipase C pathways for additional regulatory effects. The peptide's rapid and reversible receptor binding profile supports both acute and chronic experimental paradigms.

Evidence & Benchmarks

• PTH (1-34) (human) exhibits an IC50 of 2 nM for binding to recombinant human PTH1R at 25°C and physiological pH (APExBIO).
• In HEK293 cells expressing PTH1R, the peptide induces half-maximal cAMP production at 0.22 nM (APExBIO).
• Solubility exceeds 399.3 mg/mL in DMSO and 19.88 mg/mL in water, but the peptide is insoluble in ethanol (APExBIO).
• In vivo, subcutaneous administration at 10–40 μg/kg/day in male Fisher 344 rats for up to 4 weeks significantly increases trabecular and cortical bone mass (APExBIO).
• Spatially patterned kidney assembloids enable high-fidelity modeling of renal PTH1R signaling and downstream calcium handling, expanding the experimental context for PTH (1-34) studies (Huang et al., 2025).

This article extends the mechanistic focus of Parathyroid Hormone (1-34) (Human): Mechanistic Leverage... by providing quantitative, protocol-ready benchmarks and practical integration with assembloid-based kidney models.

Applications, Limits & Misconceptions

The validated PTH (1-34) peptide fragment supports bone metabolism research, osteoporosis model development, and precise dissection of serum calcium regulation. In kidney models, particularly spatially patterned assembloids, it enables high-resolution study of PTH/PTHrP receptor signaling and downstream effects on nephron function (Huang et al., 2025). However, it is not suitable for direct clinical or diagnostic applications, and its effects are limited to pathways mediated by PTH1R/PTH2R.

Common Pitfalls or Misconceptions

• PTH (1-34) (human) is not a substitute for full-length parathyroid hormone in all experimental contexts—its actions are confined to N-terminal mediated effects.
• It does not replicate the activity of parathyroid hormone-related protein (PTHrP) beyond shared receptor pathways.
• The peptide does not directly influence pathways unrelated to calcium or phosphate homeostasis.
• Long-term storage of working solutions, especially in aqueous buffers, can lead to loss of activity; use freshly prepared aliquots as recommended (APExBIO).
• Interpretation of results in non-human systems requires caution due to potential species-specific receptor pharmacodynamics.

This clarification updates the perspective in Parathyroid hormone (1-34) (human): Benchmarking a Calciu... by emphasizing experimental context boundaries and proper reagent use.

Workflow Integration & Parameters

• Reconstitution: For highest solubility, dissolve at ≥399.3 mg/mL in DMSO or ≥19.88 mg/mL in water; avoid ethanol as the peptide is insoluble.
• Storage: Store lyophilized powder desiccated at -20°C; reconstituted solutions should be used immediately and not stored long-term.
• In vitro PTH1R signaling assays: Use 0.1–10 nM for dose-response studies in receptor-expressing cells, based on cAMP induction benchmarks.
• In vivo bone mass studies: Administer subcutaneously at 10 or 40 μg/kg/day for up to 4 weeks in rat models to assess trabecular and cortical bone responses (APExBIO).
• Assembloid integration: Apply in kidney progenitor assembloid systems to probe PTH1R-mediated calcium handling and nephron development (Huang et al., 2025).

This workflow guidance builds on the strategic integration insights from Harnessing Parathyroid Hormone (1-34) (human) for Advance... by connecting validated parameters to next-generation organoid protocols.

Conclusion & Outlook

Parathyroid hormone (1-34) (human), as supplied by APExBIO, is a rigorously benchmarked tool for dissecting the molecular basis of bone metabolism and kidney function. Its quantitative activity profile, robust solubility, and compatibility with cutting-edge assembloid models support its status as a gold-standard parathyroid hormone receptor agonist for research purposes. The integration of this reagent with spatially organized kidney systems as demonstrated in recent studies (Huang et al., 2025) significantly enhances the fidelity of in vitro and in vivo disease modeling. As the field advances, continued application of PTH (1-34) peptide for bone research and nephron development is expected to clarify mechanisms of calcium homeostasis, osteoporosis, and kidney regeneration—provided that protocol, solubility, and storage guidelines are strictly followed.